VXRT - הכנסה תפעולית לפני ניכוי פחת vaxart.com
Vaxart, Inc. (VXRT) is developing innovative tablet-based vaccines for influenza and norovirus, leveraging support from BARDA and Phase 2 results. Monitoring EBITDA_Co allows for the tracking of actual cash flow, where serves as the final level marker. The business's success is based on patent protection and the confirmation of an immune response. The company is currently in the clinical testing stage, operating on grants.
Vaxart - פילוחים אנליטיים ומדדי מפתח (VXRT)
Absolute operating profit measures cash flow from core operations before depreciation and amortization, reflecting the business's ability to generate internal resources during periods of market volatility. This chart of operating profit before depreciation and amortization allows for an assessment of the financial model's resilience at Vaxart, Inc. (VXRT) amid the costly scaling of its oral vaccine platform and its dependence on government funding for clinical trials.
